Search 

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications. All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China. Glenpharma is primarily seeking Chinese partners for Licensing-out within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.;

InorbitTX is a virtual drug discovery and development company focussed on the treatment of fatty liver diseases NAFLD / NASH. Its lead project, the FXR agonist IOT022 is currently in late pre-clinical testing. IOT022 differentiates very well from competitor compounds, as it mitigates the risk for pruritus and for drug induced liver injury, seen with competitors. It gives IOT022 an excellent best-in-class opportunity. InorbitTX second project is a KHK inhibitor, IOT038, also for the treatment of NAFLD / NASH.IOT038 shows excellent astute efficacy in animals We look for funding to complete for IND and for Phase I. We also look for partnering for the Chinese / Asian market.